Contribution of prostate stem cell antigen variation rs2294008 to the risk of bladder cancer

原文： 2019 年发布于 Medicine 4 卷第 4 期 21-25  浏览量：232次

作者： Deng S. Ren Z. J. Jin T. Yang B. Dong Q.

作者单位： Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Department of Urology, Medical University of Silesia, Zabrze, Poland. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, Salzburg, Austria. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Department of Urology, Hillel Yaffe Medical Center, Hadera, Israel. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. Department of Urology, Sorbonne Université, GRC n°5, Predictive Onco-Urology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France. Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria Department of Urology, Weill Cornell Medical College, New York, NY, USA Department of Urology, University of Texas Southwestern, Dallas, TX, USA Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. Electronic address: shahrokh.shariat@meduniwien.ac.at.

归属分类：膀胱肿瘤病因/危险因素证据

DOI： 10.1007/s00345-022-04116-x

关键词： bladder cancer chemotherapy cystectomy muscle-invasive systematic review of interest.

OBJECTIVE: Several studies have compared the safety and efficacy of intravesical gemcitabine (Gem) with Bacille Calmette-Guérin (BCG) for non-muscle invasive bladder cancer. However, the results are not consistent. We carried out a meta-analysis to provide a more comprehensive analysis of the efficacy and safety of these 2 drugs. METHODS: We searched PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, and reference lists. Randomized controlled trials and retrospective controlled trials comparing intravesical Gem and BCG in adjuvant therapy for non-muscle invasive bladder cancer published in Eng-lish were included in this study. The strength of association was weighed by pooled risk ratio (RR) with 95% CIs. Sensitivity analysis was performed to examine whether the findings of the meta-analysis were robust. RESULTS: We analyzed 386 subjects from 5 pooled trials. Compared with BCG, intravesical Gem had lower incidence of dysuria (overall RR =0.31, 95% CI: 0.16, 0.61, I(2)=0%, p=0.001) and hematuria (overall RR =0.27, 95% CI: 0.11, 0.71, I(2)=0%, p=0.008). There were no statistical differences in risk of recurrence, progression, incidence of fever, and any adverse events between intravesical Gem and BCG therapy (p>0.05). No publication bias was found. CONCLUSION: This meta-analysis suggests that intravesical Gem may have similar efficacy and lower incidence of dysuria and hematuria compared with BCG. Nevertheless, we recommend additional high-quality randomized controlled trials to confirm these results.